ライフサイエンスコーパス: contrast material-enhanced

1 puted tomography (CT)-guided RF ablation and contrast material-enhanced 1-month follow-up CT and/or m

2 Delayed contrast material-enhanced 1.5-T hydrogen 1 ((1)H) magne

3 Intravenous contrast material-enhanced (100 mL of Omnipaque 350; GE

4 ght of these findings, the patient underwent contrast material-enhanced (120 mL of iopromide, Ultravi

5 Intravenous contrast material-enhanced (120 mL of Omnipaque 350; Nyc

6 and pelvis was performed and was followed by contrast material-enhanced (80 mL of iopamidol) computed

7 ts underwent portal venous phase intravenous contrast material-enhanced abdominal CT.

8 A retrospective review of contrast material-enhanced abdominal dual-energy CT scan

9 detector CT data by using a single 60-second contrast material-enhanced acquisition may be all that i

10 with attenuation values greater than 10 HU, contrast material-enhanced and delayed enhanced CT.

11 mography tumor volume and perfusion, dynamic contrast material-enhanced and diffusion-weighted magnet

12 T2 weighted, diffusion weighted, and dynamic contrast-material enhanced) and nerve-sparing robot-assi

13 y (CT) adrenal protocol (unenhanced, dynamic contrast material-enhanced, and 10-minute delayed CT) wa

14 al oblique and sagittal T2-weighted, dynamic contrast material-enhanced, and diffusion-weighted imagi

15 iparametric MR imaging (T2-weighted, dynamic contrast material-enhanced, and diffusion-weighted seque

16 d gradient-recalled acquisition, T1-weighted contrast material-enhanced, and DW imaging sequences.

17 of the IMA, the cross-sectional area of the contrast material-enhanced aortic lumen at the level of

18 The amount of necrotic tumor tissue on contrast material-enhanced arterial phase MR images and

19 nts with pancreatic adenocarcinoma underwent contrast material-enhanced biphasic multi-detector row C

20 pected of having pancreatic tumors underwent contrast material-enhanced biphasic multi-detector row c

21 Controlled extravasation of contrast material-enhanced blood (CEB) from 140 to 180 H

22 ining iodine (2, 5, and 15 mg/mL), simulated contrast material-enhanced blood, and soft-tissue insert

23 with brain tumors who underwent nine or more contrast material-enhanced brain magnetic resonance (MR)

24 very, diffusion- and perfusion-weighted, and contrast material-enhanced brain magnetic resonance (MR)

25 Forty patients underwent brain PET and contrast material-enhanced brain MR imaging, with a maxi

26 5 lesions underwent unenhanced breast CT and contrast material-enhanced breast CT before biopsy.

27 method was tested in 42 patients undergoing contrast material-enhanced cardiac MR imaging (at 1.5 T)

28 All participants underwent equilibrium contrast material-enhanced cardiac MR imaging.

29 In vivo, the contrast material-enhanced cartilage reached a steady CT

30 Baseline arterial phase contrast material-enhanced (CE) MR imaging was used to m

31 background parenchymal enhancement (BPE) at contrast material-enhanced (CE) spectral mammography and

32 ith abdominal aneurysm repair also underwent contrast material-enhanced (CE) ultrasonography (US).

33 Six esophagograms, three contrast material-enhanced chest computed tomographic (C

34 e of this study was to prospectively compare contrast material-enhanced cine magnetic resonance (MR)

35 graphic (CT) examination across a library of contrast material-enhanced computational patient models.

36 Contrast material-enhanced computed tomographic (CT) ima

37 Contrast material-enhanced computed tomographic (CT) sca

38 titutional review board waiver was obtained, contrast material-enhanced computed tomographic (CT) stu

39 vein thrombosis who were examined with both contrast material-enhanced computed tomography (CT) and

40 Nonenhanced and dynamic contrast material-enhanced computed tomography (CT) and

41 ey from unilateral nephrectomy who underwent contrast material-enhanced computed tomography (CT) at t

42 Unenhanced and contrast material-enhanced computed tomography (CT) imag

43 on tomography (PET) combined with diagnostic contrast material-enhanced computed tomography (CT) in d

44 roid prophylaxis administered 5 hours before contrast material-enhanced computed tomography (CT) is n

45 Thus, contrast material-enhanced computed tomography (CT) of t

46 Contrast material-enhanced computed tomography (CT) of t

47 ars old) underwent unenhanced MR imaging and contrast material-enhanced computed tomography (CT) of t

48 -including chest radiography; bone scanning; contrast material-enhanced computed tomography (CT) of t

49 hat were either intrinsic or demonstrated at contrast material-enhanced computed tomography (CT) or m

50 10 patients undergoing either unenhanced or contrast material-enhanced computed tomography (CT) serv

51 to prospectively evaluate the feasibility of contrast material-enhanced computed tomography (CT) with

52 re the diagnostic performance of intravenous contrast material-enhanced computed tomography (CT) with

53 dimercaptosuccinic acid (DMSA) scintigraphy, contrast material-enhanced computed tomography (CT), and

54 ion (EF) was determined retrospectively with contrast material-enhanced computed tomography (CT).

55 Posttreatment evaluation was conducted with contrast material-enhanced computed tomography in the li

56 Contrast material-enhanced computed tomography is used i

57 years) at one institution who had undergone contrast material-enhanced computed tomography of the pe

58 al phase and washout in the venous phase) at contrast material-enhanced computed tomography or magnet

59 Follow-up contrast material-enhanced computed tomography was perfo

60 atients were followed up with unenhanced and contrast material-enhanced computed tomography.

61 ation zone was identified with postprocedure contrast material-enhanced computed tomography.

62 All contrast material-enhanced (contrast group) and unenhanc

63 All contrast material-enhanced (contrast group) and unenhanc

64 h nonenhanced CT to assess calcium score and contrast material-enhanced coronary CT angiography were

65 developed for breath-hold three-dimensional contrast material-enhanced coronary magnetic resonance a

66 intravenous administration of iodixanol for contrast material enhanced CT was not an independent ris

67 corticosteroid premedication regimen before contrast material-enhanced CT (n = 1424) from 2008 to 20

68 , pelvic magnetic resonance imaging [n = 7], contrast material-enhanced CT [n = 7]) and/or surgery (n

69 cm in diameter and enhanced homogeneously on contrast material-enhanced CT and MR images.

70 gic and/or necrotic regions was best seen at contrast material-enhanced CT and MR imaging, with thick

71 e living renal donors underwent preoperative contrast material-enhanced CT angiography and gadolinium

72 nning protocol consisted of three steps: (a) contrast material-enhanced CT angiography before endovas

73 Contrast material-enhanced CT coronary angiography has b

74 the authors reviewed the report of the first contrast material-enhanced CT examination that included

75 rapy and underwent at least two preoperative contrast material-enhanced CT examinations (at least 3 m

76 Materials and Methods Contrast material-enhanced CT examinations of the chest

77 Results from 88 thoracic and 110 abdominal contrast material-enhanced CT examinations were analyzed

78 Twenty patients underwent contrast material-enhanced CT for the purpose of radiati

79 66 of 67 (98%) ablated lesions on the first contrast material-enhanced CT images at 4-8-week follow-

80 Texture was assessed for unenhanced and contrast material-enhanced CT images by using a software

81 oved study, gene expression profile data and contrast material-enhanced CT images from 70 patients wi

82 al radiologists retrospectively reviewed the contrast material-enhanced CT images obtained in six, th

83 dding unenhanced computed tomography (CT) to contrast material-enhanced CT improves the diagnostic pe

84 gh examinations; four, enteroclysis; and 19, contrast material-enhanced CT of the abdomen and pelvis

85 Dynamic contrast material-enhanced CT of the liver was performed

86 Reduced tube voltage for pediatric contrast material-enhanced CT reduces radiation dose and

87 ients 18 years and older with unenhanced and contrast material-enhanced CT results and with lesions e

88 Ninety-three abdominal-pelvic contrast material-enhanced CT scans obtained during 6 ye

89 Thin-section (2.5-mm collimation) contrast material-enhanced CT scans of 201 consecutive p

90 us cholecystitis and for whom a preoperative contrast material-enhanced CT study was available were p

91 Contrast material-enhanced CT texture parameters were as

92 Contrast material-enhanced CT was initiated 20-25 second

93 Contrast material-enhanced CT was used to assess techniq

94 Incorporating contrast material-enhanced CT with delayed imaging incre

95 3 adrenal adenomas in 193 patients (115 with contrast material-enhanced CT, 43 with unenhanced and en

96 A total of 179 patients underwent contrast material-enhanced CT, and 66 patients underwent

97 l patients underwent unenhanced and biphasic contrast material-enhanced CT.

98 ients (969 male, 1,065 female) who underwent contrast material-enhanced CT.

99 Other patients were examined with contrast material-enhanced CT.

100 To evaluate the association between dynamic contrast material-enhanced (DCE) and diffusion-weighted

101 to moderate for features related to dynamic contrast material-enhanced (DCE) imaging (kappa = 0.266-

102 The authors retrospectively analyzed dynamic contrast material-enhanced (DCE) magnetic resonance (MR)

103 low-up included US, mammography, and dynamic contrast material-enhanced (DCE) magnetic resonance (MR)

104 he performance of computer-extracted dynamic contrast material-enhanced (DCE) magnetic resonance (MR)

105 ast agent for their applicability in dynamic contrast material-enhanced (DCE) magnetic resonance (MR)

106 llular carcinoma (HCC) measured with dynamic contrast material-enhanced (DCE) magnetic resonance (MR)

107 e perfusion patterns at quantitative dynamic contrast material-enhanced (DCE) magnetic resonance (MR)

108 with DCIS who underwent preoperative dynamic contrast material-enhanced (DCE) MR imaging between 2004

109 R2)-targeted microbubbles and (b) 3D dynamic contrast material-enhanced (DCE) US by using nontargeted

110 [ADC] maps [b < 1000 sec/mm(2)], and dynamic contrast material-enhanced [DCE] MR imaging).

111 ging (diffusion-weighted MR imaging, dynamic contrast material-enhanced [DCE] MR imaging, and hydroge

112 es (T2-weighted, diffusion-weighted, dynamic contrast material-enhanced [DCE] pulse sequences) and sc

113 ith carotid atherosclerosis, double-oblique, contrast material-enhanced, double inversion-recovery, f

114 consecutive dynamic susceptibility-weighted contrast material-enhanced (DSC) MR acquisitions, which

115 Contrast material-enhanced dual-energy CT and convention

116 Purpose To determine whether single-phase contrast material-enhanced dual-energy material attenuat

117 nonenhanced 120-kVp CT images were acquired, contrast material-enhanced dual-energy multidetector CT

118 cinoma at pathologic analysis, who underwent contrast material-enhanced dual-energy nephrographic pha

119 Contrast material-enhanced dual-phase multidetector row

120 ted and fat-saturated T2-weighted images and contrast material-enhanced dynamic three-dimensional (3D

121 performed by using gradient-echo and dynamic contrast material-enhanced echo-planar pulse sequences b

122 Patients underwent contrast material-enhanced electrocardiography-gated car

123 t male heart transplant recipients underwent contrast material-enhanced electron-beam computed tomogr

124 resia underwent 48 cardiac-triggered dynamic contrast material-enhanced electron-beam CT studies.

125 Patients were examined with contrast material-enhanced fat-suppressed T1-weighted 4.

126 rying iodinated contrast agent to create the contrast material-enhanced five-dimensional XCAT models,

127 When tumors were approximately 600 mm3, contrast material-enhanced gray-scale US was performed,

128 The first contrast material-enhanced GRE acquisition was timed for

129 , mass effect, or hydrocephalus (HMH) at non-contrast material-enhanced head computed tomographic (CT

130 ts with known malignancy underwent abdominal contrast material-enhanced helical CT and MR imaging fro

131 uated at CT, is best detected with triphasic contrast material-enhanced helical imaging performed wit

132 The contrast material-enhanced (ie, arthrographic and bursog

133 ted turboFLASH technique was used to acquire contrast material-enhanced images 19 days +/- 7 (SD) aft

134 the difference in R2* (DeltaR2*) between the contrast material-enhanced images and baseline images.

135 Contrast material-enhanced images can depict and be used

136 Endoleaks on contrast material-enhanced images were considered the re

137 lower in attenuation than the thyroid on non-contrast material-enhanced images, but patterns differed

138 wo observers of DW, T2-weighted, and dynamic contrast material-enhanced images, pathologic data, and

139 33.3% for width measurements on T1-weighted contrast material-enhanced images.

140 The neonates who underwent contrast material-enhanced imaging and the neonates who

141 T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced imaging before prostatectomy

142 Cine-phase contrast material-enhanced imaging of the renal arteries

143 Advanced contrast material-enhanced imaging techniques are capabl

144 culitis that were not seen at unenhanced and contrast material-enhanced imaging with gadopentetate di

145 T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced imaging) obtained before radi

146 T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced imaging, and by using the sum

147 T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced imaging, were included.

148 ing, diffusion-weighted imaging, and dynamic contrast material-enhanced imaging, with a pelvic phased

149 ighted, diffusion-weighted [DW], and dynamic contrast material-enhanced imaging.

150 reoperative work-up included a water-soluble contrast material-enhanced (iodixanol, 320 mg of iodine

151 t magnetic resonance (MR) imaging, including contrast material-enhanced LGE imaging and T1 mapping.

152 with tissue-equivalent materials to simulate contrast material-enhanced liver, spleen, pancreas, aort

153 ntrolled apnea improves the image quality of contrast material--enhanced magnetic resonance (MR) angi

154 d in a time series of three-dimensional (3D) contrast material-enhanced magnetic resonance (MR) angio

155 nocrystalline iron oxide nanoparticle-47 for contrast material-enhanced magnetic resonance (MR) angio

156 se 3.0-T breath-hold high-spatial-resolution contrast material-enhanced magnetic resonance (MR) angio

157 technique to acquire high-spatial-resolution contrast material-enhanced magnetic resonance (MR) angio

158 rch and branch vessels underwent breath-hold contrast material-enhanced magnetic resonance (MR) angio

159 examinations performed before acquisition of contrast material-enhanced magnetic resonance (MR) angio

160 mpared two techniques for performing runoff, contrast material-enhanced magnetic resonance (MR) angio

161 rmined for triggering three-dimensional (3D) contrast material-enhanced magnetic resonance (MR) angio

162 a in situ (DCIS) lesions depicted on dynamic contrast material-enhanced magnetic resonance (MR) image

163 Dynamic contrast material-enhanced magnetic resonance (MR) image

164 nts with GBM underwent baseline imaging with contrast material-enhanced magnetic resonance (MR) imagi

165 eters at baseline were estimated by means of contrast material-enhanced magnetic resonance (MR) imagi

166 tronic medical records were searched for all contrast material-enhanced magnetic resonance (MR) imagi

167 At the time of contrast material-enhanced magnetic resonance (MR) imagi

168 To retrospectively compare three dynamic contrast material-enhanced magnetic resonance (MR) imagi

169 phy (SPECT), dynamic susceptibility-weighted contrast material-enhanced magnetic resonance (MR) imagi

170 ression patterns in tumors, the authors used contrast material-enhanced magnetic resonance (MR) imagi

171 Contrast material-enhanced magnetic resonance (MR) imagi

172 Images obtained at contrast material-enhanced magnetic resonance (MR) imagi

173 ffectiveness ratio of dynamic susceptibility contrast material-enhanced magnetic resonance (MR) imagi

174 (n = 16), ultrasonography (US) (n = 8), and contrast material-enhanced magnetic resonance (MR) imagi

175 equence paradigm and limited role of dynamic contrast material-enhanced magnetic resonance (MR) imagi

176 e-matched control subjects underwent dynamic contrast material-enhanced magnetic resonance (MR) imagi

177 Post-PAE prostate ischemia was measured with contrast material-enhanced magnetic resonance (MR) imagi

178 east 10 mm were recruited to undergo dynamic contrast material-enhanced magnetic resonance (MR) imagi

179 Contrast material-enhanced magnetic resonance (MR) imagi

180 ured at baseline and after the first TACE on contrast material-enhanced magnetic resonance images.

181 me were assessed with dynamic susceptibility contrast material-enhanced magnetic resonance imaging in

182 Contrast material-enhanced magnetic resonance imaging of

183 neoplasms with magnetic susceptibility-based contrast material-enhanced magnetic resonance imaging.

184 Forty-two contrast material-enhanced MR angiographic examinations

185 onance (MR) angiography was compared with 3D contrast material-enhanced MR angiography in patients su

186 g systems to perform multistation peripheral contrast material-enhanced MR angiography in the lower e

187 men, 18 women; mean age, 64 years) underwent contrast material-enhanced MR angiography of the lower e

188 -T three-dimensional high-spatial-resolution contrast material-enhanced MR angiography of the supraao

189 onic peripheral arterial disease (PAD), with contrast material-enhanced MR angiography serving as the

190 Contrast material-enhanced MR angiography was also perfo

191 Materials and Methods Contrast material-enhanced MR angiography was performed

192 This preliminary work shows that contrast material-enhanced MR angiography with intraarte

193 splants underwent SSFP MR angiography before contrast material-enhanced MR angiography.

194 ar disease underwent multistation whole-body contrast material-enhanced MR angiography.

195 heral vascular disease, underwent peripheral contrast material-enhanced MR angiography.

196 ombined with US were considered for a single contrast material-enhanced MR examination within 8 weeks

197 nd organ-specific scan delay optimization at contrast material-enhanced MR image evaluation.

198 red with the nonperfused regions measured on contrast material-enhanced MR images by using the Bland-

199 Contrast material-enhanced MR images obtained minutes af

200 Contrast material-enhanced MR images showed large but id

201 imensional ablation lengths were measured on contrast material-enhanced MR images, and bone remodelin

202 s correlated well with diameters measured at contrast material-enhanced MR imaging (mean difference b

203 Delayed contrast material-enhanced MR imaging allowed simultaneo

204 Participants underwent contrast material-enhanced MR imaging and fluorine 18 fl

205 11, 58 premenopausal women who had undergone contrast material-enhanced MR imaging and MR imaging-gui

206 All participants underwent contrast material-enhanced MR imaging and ultrasonograph

207 se margins of resection) underwent bilateral contrast material-enhanced MR imaging at 1.5 T with a de

208 23 patients with nipple discharge underwent contrast material-enhanced MR imaging at 1.5 T.

209 ance (MR) imaging and dynamic susceptibility contrast material-enhanced MR imaging at baseline and at

210 Women underwent standard dynamic contrast material-enhanced MR imaging for further assess

211 Contrast material-enhanced MR imaging has the potential

212 n and compared with cross-registered delayed contrast material-enhanced MR imaging in five healthy vo

213 3)Na and DWI sequences were performed before contrast material-enhanced MR imaging in patients with b

214 Clinical applications of contrast material-enhanced MR imaging include the detect

215 Dynamic contrast material-enhanced MR imaging of nine tumors sho

216 Dynamic contrast material-enhanced MR imaging of one tumor showe

217 terial vessel wall imaging at unenhanced and contrast material-enhanced MR imaging of the aortic, car

218 MR renography was performed along with contrast material-enhanced MR imaging of the kidneys and

219 T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced MR imaging prior to radical p

220 es measuring at least 1 cm who underwent two contrast material-enhanced MR imaging studies at least 3

221 a System category 4 or 5 at clinical dynamic contrast material-enhanced MR imaging that subsequently

222 T2- and T1-weighted dynamic contrast material-enhanced MR imaging was performed befo

223 Dynamic contrast material-enhanced MR imaging was performed by u

224 Dynamic contrast material-enhanced MR imaging was performed with

225 All studies in which contrast material-enhanced MR imaging was used for asses

226 In coinjection tumors, dynamic contrast material-enhanced MR imaging was used to measur

227 T2-weighted; diffusion-weighted; and dynamic contrast material-enhanced MR imaging with a 3-T imager

228 renal lesions evaluated by means of dynamic contrast material-enhanced MR imaging with serial breath

229 ighted MR imaging, 0.42 and 0.28; at dynamic contrast material-enhanced MR imaging, 0.23 and 0.24, an

230 With contrast material-enhanced MR imaging, additional tissue

231 nal (3D) high-spatial-resolution T1-weighted contrast material-enhanced MR imaging, dynamic contrast-

232 al depictions of iceballs were compared with contrast material-enhanced MR imaging-based estimates of

233 Imaging included perfusion and T1-weighted contrast material-enhanced MR imaging.

234 and physical examination findings underwent contrast material-enhanced MR imaging.

235 is: noncontrast MR cholangiopancreatography, contrast material-enhanced MR imaging/MR cholangiopancre

236 All patients underwent a non-contrast material-enhanced MR protocol that included rou

237 ment of the normal small-bowel wall by using contrast material-enhanced multi-detector row computed t

238 mation was removed from clinical images from contrast material-enhanced multi-detector row CT examina

239 ion of the normal urinary collecting system, contrast material-enhanced multi-detector row CT urograp

240 s were discovered incidentally at multiphase contrast material-enhanced multidetector computed tomogr

241 The patient underwent contrast material-enhanced multidetector computed tomogr

242 onary stenosis was induced in seven dogs and contrast material-enhanced multidetector CT was performe

243 tient underwent erect abdominal radiography, contrast material-enhanced multidetector row computed to

244 T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced multiparametric MR imaging of

245 Contrast material-enhanced multiphase MR imaging was per

246 Contrast material-enhanced myocardial perfusion imaging

247 h advanced HNSCC (stage III or IV) underwent contrast material-enhanced neck CT, CT perfusion imaging

248 mage signal intensities in regions that were contrast material enhanced on T1-weighted 1H images (tum

249 examine the subsequent quantitative dynamic contrast material-enhanced parameters in breast cancer w

250 Contrast material-enhanced pelvic MR imaging was perform

251 omas, 18 metastases) underwent conventional, contrast material--enhanced perfusion-weighted, and prot

252 xamined with dynamic susceptibility-weighted contrast material-enhanced perfusion magnetic resonance

253 xamined with dynamic susceptibility-weighted contrast material-enhanced perfusion magnetic resonance

254 ges were acquired in unenhanced and standard contrast material-enhanced phases, with observation diam

255 ic cord occlusion, testicular Doppler US and contrast material-enhanced PI imaging were performed.

256 d a gadolinium-filled capsule representing a contrast material-enhanced polyp was positioned on the c

257 -scale US and power Doppler) was followed by contrast material-enhanced power Doppler and gray-scale

258 ging in comparison with full multiparametric contrast material-enhanced prostate MR imaging in men wi

259 nventional coronary catheter angiography and contrast material-enhanced retrospectively electrocardio

260 d PET/MR imaging with diffusion-weighted and contrast material-enhanced sequences after unenhanced PE

261 s currently include multiple nonenhanced and contrast material-enhanced sequences.

262 se To compare the diagnostic performances of contrast material-enhanced spectral mammography and brea

263 Contrast material-enhanced spinal MR images obtained in

264 w was performed of findings from surgery and contrast material-enhanced spiral and conventional CT pe

265 Contrast material-enhanced spiral CT scans obtained in 9

266 retrospectively reviewed 186 arterial phase contrast material-enhanced spiral CT scans of the abdome

267 the entire primary tumor were assessed with contrast material-enhanced staging CT studies obtained i

268 Patients underwent diagnostic contrast material-enhanced study prior to the first dila

269 dial iron quantification, and unenhanced and contrast material-enhanced T1 mapping.

270 /- 0.83 [SD]), followed by those measured on contrast material-enhanced T1-weighted (1.27 mm +/- 0.83

271 texture features) from the multiparametric (contrast material-enhanced T1-weighted and fluid-attenua

272 , intermediate-weighted, time-of-flight, and contrast material-enhanced T1-weighted images.

273 cluded T1-weighted, T2-weighted, and dynamic contrast material-enhanced T1-weighted imaging.

274 Disruption was evaluated at contrast material-enhanced T1-weighted magnetic resonanc

275 attenuated inversion recovery, and high-dose contrast material-enhanced T1-weighted MR imaging at 6-m

276 After the procedure, T2-weighted and contrast material-enhanced T1-weighted MR imaging were p

277 using software at T2-weighted MR imaging and contrast material-enhanced T1-weighted MR imaging.

278 short inversion time inversion-recovery, and contrast material-enhanced T1-weighted whole-body MR ima

279 n at 7 and 14 days after the procedure (with contrast material-enhanced T1-weighted, T2-weighted, and

280 Two operators rated contrast material-enhanced, T1-weighted axial magnetic r

281 jury was evaluated in 21 patients by using a contrast material-enhanced T1rho-weighted cine turbo fie

282 On T1-weighted (unenhanced and contrast material-enhanced), T2-weighted, and DWI (b = 1

283 ospectively evaluate high-spatial-resolution contrast material-enhanced three-dimensional (3D) magnet

284 ension were examined at 1.5 T with a dynamic contrast material-enhanced three-dimensional fast low-an

285 se the spatial and/or temporal resolution in contrast material-enhanced three-dimensional magnetic re

286 MR imaging throughout the heart, followed by contrast material-enhanced time-resolved three-dimension

287 Purpose To demonstrate the feasibility of contrast material-enhanced ulrasonographic (US) nephrost

288 Purpose To assess whether contrast material-enhanced ultrasonography (US) can be u

289 can be reproduced in future clinical trials, contrast material-enhanced ultrasound (US) of targeted M

290 To characterize the effect of low-frequency contrast material-enhanced ultrasound on the vascular en

291 Results at contrast material-enhanced US angiography and duplex US

292 In vivo imaging signals of contrast material-enhanced US by using anti-VEGFR2-targe

293 ember 2008 and May 2009 with late-phase (LP) contrast material-enhanced US by using flash imaging wit

294 Targeted contrast material-enhanced US imaging signal by using MB

295 In vivo targeted contrast material-enhanced US imaging signal using the t

296 icle describes the successful integration of contrast material-enhanced US into a multimodality appro

297 Targeted contrast material-enhanced US signal was quantified 5 mi

298 In vivo targeted contrast material-enhanced US signal was quantitatively

299 eft anterior descending artery (LAD), and 20 contrast material-enhanced volume scans were acquired pe

300 ypes 1 and 2) who underwent a comprehensive, contrast material-enhanced whole-body MR imaging protoco